Condition
Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder) clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder) clinical trials that are recruiting, at sites in 2 countries (most in Italy (1), United States (1)). By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs
This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.
-
Nucleoside treatment for telomere biology disorders
This will try whether taking two oral nucleosides (deoxycytidine and deoxythymidine) for 24 weeks is safe and may change blood, bone marrow, or lung problems in people aged 1–70 with telomere biology disorders.
Related topics
Quick answers
How many Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder) clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Italy (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.